Hologic Inc. Files 2024 10-K Report

TL;DR

Hologic dropped its 2024 10-K. Check financials & biz ops.

AI Summary

Hologic Inc. filed its 10-K for the fiscal year ending September 28, 2024, reporting on its financial performance and business operations. The company, headquartered in Marlborough, MA, is involved in the X-ray apparatus and tubes industry. This filing provides a comprehensive overview of its fiscal year, including financial statements and business disclosures.

Why It Matters

This 10-K filing provides investors and stakeholders with a detailed look into Hologic's financial health, strategic direction, and potential risks for the fiscal year 2024, influencing investment decisions.

Risk Assessment

Risk Level: medium — The filing covers a full fiscal year and includes standard disclosures for a public company, but the complexity of financial reporting and business operations inherently carries medium risk.

Key Numbers

• 20240928 — Fiscal Year End (The report covers the period ending on this date.)
• 2023-10-01 — Fiscal Year Start (The report covers the period starting from this date.)

Key Players & Entities

• HOLOGIC INC (company) — Filer
• MARLBOROUGH (location) — Business Address City
• MA (location) — Business Address State
• 01752 (location) — Business Address Zip
• 20240928 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.01 — ange on which Registered Common Stock, $0.01 par value HOLX The NASDAQ Global Select

Filing Documents

• holx-20240928.htm (10-K) — 3029KB
• ex46-2029notesxsecondsuppl.htm (EX-4.6) — 22KB
• ex412-2028notesxsixthsuppl.htm (EX-4.12) — 22KB
• ex1053-dewaltsevandcicx919.htm (EX-10.53) — 95KB
• finalex1055-formofrsuagree.htm (EX-10.55) — 39KB
• ex1058-250campusdrivexseco.htm (EX-10.58) — 16KB
• ex1059-250campusdrivexthir.htm (EX-10.59) — 54KB
• ex19-hologicxinsidertradin.htm (EX-19) — 70KB
• ex211-subsidiariesofhologi.htm (EX-21.1) — 46KB
• holxq4-2024ex231.htm (EX-23.1) — 5KB
• holxq4-2024ex311.htm (EX-31.1) — 9KB
• holxq4-2024ex312.htm (EX-31.2) — 9KB
• holxq4-2024ex321.htm (EX-32.1) — 5KB
• holxq4-2024ex322.htm (EX-32.2) — 5KB
• holx-20240928_g1.jpg (GRAPHIC) — 58KB
• 0000859737-24-000024.txt ( ) — 17882KB
• holx-20240928.xsd (EX-101.SCH) — 111KB
• holx-20240928_cal.xml (EX-101.CAL) — 161KB
• holx-20240928_def.xml (EX-101.DEF) — 548KB
• holx-20240928_lab.xml (EX-101.LAB) — 1252KB
• holx-20240928_pre.xml (EX-101.PRE) — 943KB
• holx-20240928_htm.xml (XML) — 3330KB

Risk Factors

Item 1A. Risk Factors 18

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 30 Item 1C. Cybersecurity 31

Properties

Item 2. Properties 32

Legal Proceedings

Item 3. Legal Proceedings 32

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 32 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 33

Reserved

Item 6. Reserved 34

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 51

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 52

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 52

Controls and Procedures

Item 9A. Controls and Procedures 52

Other Information

Item 9B. Other Information 56 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 56 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 57

Executive Compensation

Item 11. Executive Compensation 57

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 57

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 57

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 58 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 59

Form 10-K Summary

Item 16. Form 10-K Summary 65 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this report and documents incorporated by reference herein are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding: the development of new or improved competitive technologies and products; the anticipated development of markets we sell our products into and the success of our products in these markets; our ability to predict accurately the demand for our products, and products under development and to develop strategies to address markets successfully; the anticipated performance and benefits of our products; business strategies; the effect of consolidation in the healthcare industry; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions we may complete in the future; the coverage and reimbursement decisions of third-party payors; the uncertainty of the impact of cost containment efforts and federal healthcare reform legislation on our business and results of operations; the guidelines, recommendations, and studies published by various organizations relating to the use of our products; our ability to obtain and maintain regulatory approvals and clearances for our products, including the implementation of the European Union Medical Device and In Vitro Diagnostic Regulation requirements, and maintain compliance w

Business

Item 1. Business Overview We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. We sell and service our products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives. We operate in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Through our Diagnostics segment, we offer a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. Our primary Diagnostics products include our molecular diagnostic assays, which run on our advanced instrumentation systems (Panther and Panther Fusion), our ThinPrep cytology system, including our Genius Digital Diagnostics System, and the Rapid Fetal Fibronectin Test. Our Aptima family of molecular diagnostic assays is used to detect, among other things, the infectious microorganisms that cause common sexually transmitted diseases, or STDs, such as chlamydia and gonorrhea, or CT/NG; certain high-risk strains of human papillomavirus, or HPV; Trichomonas vaginalis , the parasite that causes trichomoniasis; Mycoplasma genitalium; and Herpes Simplex viruses 1 and 2. We also offer viral load tests for the quantitation of Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, or HIV-1, and human cytomegalo virus, or CMV, for use on our Panther instrument system. In addition, we offer bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year. Our assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or GBS, that are run on the Panther Fu

View Full Filing

View this 10-K filing on SEC EDGAR